Neuronetics EPS Beats Consensus as Revenue Stabilizes at $41.6M
Neuronetics closed at $2.90 after reporting a better-than-expected loss per share, though the stock remains below its 52-week high.
Neuronetics, Inc. (Nasdaq: STIM) closed trading at $2.90 on September 19, 2026, following a quarterly report released on August 11 that showed a narrower loss than expected. The company reported revenue of $41.57 million and earnings per share of negative $0.05, outperforming the consensus estimate of negative $0.12 by $0.07. This performance underscores the firm’s position in the healthcare equipment sector, where margin management remains a key operational focus.
Despite the positive earnings surprise, the share price remains 15.7% below the 52-week high of $3.44 and sits 262.5% above the low of $0.80. With a market capitalization of $220.98 million and daily volume of 1.12 million shares, the stock trades in a range that reflects cautious investor sentiment. The gap between the current price and the consensus target of $4.67 highlights the distance the company must bridge to align market valuation with its recent operational results.
Quarterly Financial Performance
The August 11 earnings release marked a deviation from analyst projections, primarily driven by the EPS beat. By reducing the net loss per share to $0.05 against an expected $0.12, Neuronetics demonstrated improved cost control or revenue mix within its $41.57 million top line. This specific beat of $0.07 per share is a tangible metric of the company’s ability to manage its bottom line in a competitive healthcare equipment market.
Market Valuation Context
Market data from GN stocks/earnings-beat indicates a strong buy consensus, with five buy ratings and one sell rating, but no hold recommendations. This skew suggests that while investors acknowledge the recent EPS improvement, they are waiting for further confirmation in revenue growth or margin expansion. The 61% gap between the $2.90 closing price and the $4.67 average target indicates that the market has not yet fully priced in the company’s potential upside.
Future Price Catalysts
The next significant catalyst will likely determine whether the stock reclaims its 52-week high of $3.44. Current trading levels suggest that the prior earnings beat has been partially digested, and further upward movement requires new fundamental drivers. Investors are focused on how the company sustains its improved EPS trajectory while navigating the broader healthcare equipment supply landscape.
